We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Adaptimmune Named as One of “Fierce 15” Biotech Companies of 2014
News

Adaptimmune Named as One of “Fierce 15” Biotech Companies of 2014

Adaptimmune Named as One of “Fierce 15” Biotech Companies of 2014
News

Adaptimmune Named as One of “Fierce 15” Biotech Companies of 2014

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Adaptimmune Named as One of “Fierce 15” Biotech Companies of 2014"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Adaptimmune has announced that it has been named by FierceBiotech as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

Adaptimmune is focused on the use of T-cell therapy to treat cancer and infectious disease. Using its unique T-cell receptor (TCR) engineering technology, the company has created TCRs which are deployed to target the cancer testis antigen, NY-ESO-1, as well as other targets.

Adaptimmune is running trials across the United States in multiple myeloma, melanoma, sarcoma and ovarian cancer and in June announced a strategic collaboration and licensing agreement with GlaxoSmithKline.

“Adaptimmune CEO James Noble has endured plenty of ups and downs over the years, but GSK’s recent deal puts the U.K. biotech at center stage on TCRs, a hot field in the oncology arena,” says John Carroll, editor of FierceBiotech. “We’ve watched the progress of their sister company - Immunocore - and now we’ll keep a close eye on Adaptimmune’s progress in the clinic.”

James Noble, Chief Executive Officer of Adaptimmune, commented: “We are delighted to be listed by FierceBiotech among the top private biotech firms globally. This award recognizes years of hard work by a dedicated and highly skilled team to develop our technology, culminating in the completion of a major partnership deal with GSK this summer.”

The Fierce 15 celebrates the spirit of being “fierce” - championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s twelfth annual Fierce 15 selection. A complete list of “Fierce 15” companies can be found online at www.fiercebiotech.com/fierce15.

An internationally recognized daily report reaching a network of over 270,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories.

Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

Advertisement